DWA
MRTX

Dorsey Wright & Associates’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Dorsey Wright & Associates’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-490
Closed -$23K – 361
2018
Q3 		$23K Buy
+490
New +$27.3K ﹤0.01% 142

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Dorsey Wright & Associates's MRTX Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2018, closing a stake of 490 shares — an estimated $23K sold.

Dorsey Wright & Associates first reported a position in MRTX in Q3 2018 and held it in 1 quarter. The position peaked at $23K in Q3 2018. 112 funds tracked by Wall St. Rank hold MRTX as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 490 Mirati Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $23K.
  • Dorsey Wright & Associates first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Mirati Therapeutics, Inc. Common Stock position peaked at $23K in Q3 2018.
  • 112 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.